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October 2009966 AbstractsResults: During this period, 6404 CEAs were performed for asymp-
tomatic disease; 102 (2%) for stenoses of 60%-69%, 758 (12%) of 70%-79%
stenosis, 2263 (35%) for 80%-89% stenosis, and 3281 (51%) for 90%-99%
stenosis. Risk factors were similar in all groups. Shunt utilization was higher
in the 60%-69% stenosis group than the others. In the 60%-69% group there
were no strokes and no deaths, in the 70%-79% group there were two (0.3%)
deaths and two (0.6%) strokes. In the 80%-89% group there were 12 (0.5%)
deaths, 11 permanent neurologic deficits, and two temporary neurologic
deficits (0.6%). In the 90%-99% group, there were 23 (0.7%) mortalities, five
(0.2%) temporary neurological deficits (TND), and nine (0.3%) permanent
strokes. The most common non-neurologic complication was postoperative
hematoma at 1.4% and was consistent throughout all groups. Mean fol-
low-up averaged 48 months.
Conclusions: Patients presenting with moderate 60% to 69% stenoses
can be treated safely with carotid endarterectomy. All asymptomatic patients
over 60% stenosis had an acceptably low mortality and morbidity in this
series.
Durability of Infrainguinal Interventions in Patients with Severely
Disabling Claudication and TASC II C and D Femoropopliteal Disease
Dosluoglu HH, Lall P, Harris LM, Dryjski ML
Objectives: Durability of open and endovascular interventions on
patients with disabling claudication is a major concern, especially in those
with complex anatomy needing infrainguinal reconstructions. The goal of
our study was to compare our results of bypass versus endovascular inter-
ventions in a consecutive patient series and to determine effectiveness of
treatment modality.
Methods: All patients who presented with severely disabling claudica-
tion (Rutherford 3) with TASC II C or D disease, who underwent bypass, or
infrainguinal endovascular (EV) interventions following failure of medical
management between June 2001 and December 2008 were included.
Results:There were 56 patients in the EV group, and 56 patients in the
open group. The comorbidities were similar, except there were more active
smokers (68% vs. 46%, P .035) and prior ipsilateral revascularizations (38%
vs. 7%, P  .001) in the open group. Fifty-nine percent of bypasses were
performed using polytetrafluoroethylene (PTFE). There were no 30-day
postoperative mortalities. There were four superficial infections, one deep
infection (necessitating graft removal), and one perigraft seroma in the open
group. Technical success was 95% in the EV group. Length of stay was
significantly less in the EV group (1.0  1.3 vs. 5.1  4.1 days, P  .001).
The mean ankle-brachial index (ABI) increased from 0.55 to 0.94, similar in
both groups. The mean follow-up was 29 22 months. Primary, secondary
patency, sustained clinical success rates (clinical improvement, freedom from
target extremity revascularization (TER]), secondary clinical success (with
TER) were similar (Table I), with a 36-month survival rate of 91 4%. Only
one patient had an amputation in the open group at 32 months. Fifteen
patients (27%) in open and 20 patients (36%) in EV group required ipsilat-
eral reinterventions (Table II; P  .419).
Conclusions: Clinical benefit following endovascular and open inter-
ventions in patients with severely disabling claudication and TASC II C or D
femoropopliteal disease is similar at three years. The clinical improvement
without additional procedures is achieved only in half, and TER is required
in about a third of the patients. Aggressive medical management of claudi-
cation is warranted before any (open or endovascular) interventions are
planned, and patients should be informed of the expected outcomes.
Table I. Patency rates and sustained and secondary
clinical success rates
PP SP SusClSuc SecClSuc
12 mo 36 mo 12 mo 36 mo 12 mo 36 mo 12 mo 36 mo
Open 79%  6% 59%  8% 82%  6% 71%  8% 77%  6% 58%  8% 85%  5% 75%  7%
EV 69%  7% 54%  8% 86%  5% 69%  9% 67%  7% 48%  8% 92%  4% 80%  8%
P .162 .942 .120 .387
EV, Endovascular; PP, primary patency; SecCLSuc, secondary clinical suc-
cess; SP, secondary patency; SusClSuc, sustained clinical success.Table II. Reinterventions in open and EV-treated groups
Reinterventions Open EV
Thrombolysis  PTA/S 6 8
Repeat bypass 5 7
EV recanalization 2 1
Inflow/runoff EV intervention 2 8
Contralateral revascularization 5 7
Contralateral amputation 2 0
EV, Endovascular; PTA/S, percutaneous transluminal angioplasty/stent.
Salvage after Failed Surgical Bypass: Effectiveness of Endovascular
Recanalization of Native Lower Extremity Arterial Occlusions
Dayal R , Graham AR , Khan H, et al
Objectives:The purpose of this study was to determine the outcome of
endovascular interventions of the native circulation after failed lower extrem-
ity bypass grafting.
Methods: A prospective registry encompassing all patients treated for
lower extremity atherosclerotic disease from May 2004 to September 2008
was established. Patients were followed with duplex ultrasound and ankle-
brachial index/pulse volume recording (ABI/PVR) at one, three, six, and
12 months and annually. Patients treated after failed lower extremity bypass
grafting were identified and angiogram, duplex, and ABI data abstracted.
Patients with similar comorbidities and lesion characteristics not treated with
prior bypass grafting were used as comparison. Statistical analysis was per-
formed using Kaplan-Meier and log-rank analysis.
Results: One thousand nine hundred and thirty eight lower extremity
arterial lesions were treated in 826 patients. Seventy-four arterial lesions in 39
patients were treated in those who had undergone prior bypass grafting (BPG).
Indications were claudication (n  16, 38.5%), rest pain (n  8, 17.9%), and
tissue loss (n  15, 43.6%). Prior bypass were femoral to popliteal (71.8%),
femoral to tibial (25.6%), and external iliac to popliteal (2.6%). Mean follow-up
was 13.7 11.5months. Comparison to a corresponding group of non-bypass
graft patients (NBPG) revealed that there was no significant difference in
primary, assisted primary, secondary patencies, or limb salvage in patients
treated with prior BPG (Table I) when the indication for treatment was critical
limb ischemia (CLI). In contrast, comparison to a corresponding group of
NBPG revealed that there was significant decrease in primary, assisted primary,
and secondary patency in patients treated with prior BPG (Table II) when the
indication for treatment was claudication. This difference persisted even when
corrected for comorbidities and lesion characteristics. Lesion length, percent
stenosis, and percent chronic total occlusion were 162.7 139.7 and 130.3
56.9 (P .21), 88.4 11.0 and 90.1 12.1 (P .47), 34.4% and 49.7% (P
.12) for BPG and NBPG lesions, respectively.
Conclusions: Endovascular salvage of native arterial occlusions after
failed surgical bypass achieves acceptable patency and limb salvage in patients
with CLI. Conversely, patients with claudication that are subsequently
treated with endovascular methods have poor long-term patency and require
multiple endovascular interventions to maintain patency.
Table I. Patency and limb salvage rates in CLI patients
treated with endovascular modalities
6 mo 12 mo 18 mo 24 mo 30 mo
Primary patency BPG 74.6  7.3 51.2  8.9 33.4  9.3 33.4  9.3 11.1  9.6
Primary patency
No BPG
69.2  3.7
P  .59
51.0  4.4
P  .95
42.1  4.6
P  .68
35.2  4.8
P  .860
35.2  4.8
P  .556
Primary assisted
patency BPG
83.2  6.3 58.8  9.0 49.3  9.8 49.3  9.8 49.3  9.8
Primary assisted
patency
No BPG
73.0  3.6
P  .26
60.3  4.3
P  .90
53.1  4.7
P  .98
45.6  5.1
P  .78
43.7  5.2
P  .74
Secondary patency
BPG
83.1  6.3 72.0  8.1 61.3  9.8 61.3  9.8 61.3  9.8
Secondary patency
No BPG
78.2  3.3
P  .57
71.7  3.9
P  .88
64.5  4.5
P  .95
57.9  5.1
P  .86
55.9  5.3
P  .82
Limb salvage BPG 85.4  6.0 76.9  7.9 76.9  7.9 76.9  7.9 76.9  7.9
Limb salvage
No BPG
86.1  2.8
P  .89
80.2  3.5
P  .75
77.6  3.9
P  .88
75.4  4.4
P  .94
71.9  5.4
P  .98
BPG, Bypass grafting; CLI, critical limb ischemia.
